IR415 |
| Catalog No.GC61455 |
IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 452967-14-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (Kd=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease[1]. HBx: hepatitis B virus X protein.
Hepatitis B virus X protein (HBx) as a suppressor of host defenses consisting of RNAi-based silencing of viral genes[1].IR415 (50-200 μM) has a dose-dependent inhibitory effect on HBx, with a minimal effective concentration of 50 μM in HepG2/GFP-shRNA line transfected with HBx[1].
[1]. Ghosh S, et al. An RNAi-based high-throughput screening assay to identify small molecule inhibitors of hepatitis B virus replication.J Biol Chem. 2017 Jul 28;292(30):12577-12588.
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *